XNAS
ZURA
Market cap80mUSD
Jul 14, Last price
1.30USD
1D
-0.76%
1Q
14.04%
IPO
-82.04%
Name
Zura Bio Ltd
Chart & Performance
Profile
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2022‑03 | 2021‑12 | |
Income | |||||
Revenues | |||||
Cost of revenue | 55,189 | 43,999 | 26,364 | ||
Unusual Expense (Income) | |||||
NOPBT | (55,189) | (43,999) | (26,364) | ||
NOPBT Margin | |||||
Operating Taxes | (7,017) | (203) | (570) | ||
Tax Rate | |||||
NOPAT | (48,172) | (43,796) | (26,364) | ||
Net income | (45,386) -24.81% | (60,360) -1,800.70% | 3,549 -57.83% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 60,757 | 116,407 | 10,000 | ||
BB yield | -32.37% | -75.39% | |||
Debt | |||||
Debt current | 356 | ||||
Long-term debt | 12,500 | ||||
Deferred revenue | |||||
Other long-term liabilities | 990 | (8,072) | |||
Net debt | (176,498) | (99,806) | 12,842 | ||
Cash flow | |||||
Cash from operating activities | (28,076) | (15,054) | (1,071) | ||
CAPEX | (75) | (12,000) | |||
Cash from investing activities | (5,075) | (8,000) | (12,000) | ||
Cash from financing activities | 109,843 | 121,293 | 356 | ||
FCF | (48,263) | (58,225) | (11,935) | ||
Balance | |||||
Cash | 176,498 | 99,806 | 14 | ||
Long term investments | |||||
Excess cash | 176,498 | 99,806 | 14 | ||
Stockholders' equity | (144,227) | (83,269) | 119,319 | ||
Invested Capital | 304,246 | 163,810 | (9,214) | ||
ROIC | 286.12% | ||||
ROCE | |||||
EV | |||||
Common stock shares outstanding | 75,071 | 33,064 | 17,250 | ||
Price | 2.50 -46.47% | 4.67 | |||
Market cap | 187,677 21.55% | 154,409 | |||
EV | 22,842 | 74,824 | |||
EBITDA | (55,180) | (43,999) | (26,364) | ||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT |